Listed Medical Marijuana Companies
Disclaimer: I am NOT a financial advisor and am NOT recommending anyone to buy any of these stocks, this is just a list of some of the many stocks out there with some information about the companies involved.
Marijuana stocks have had an amazing year, and changes in laws, thinking and legalisations in 2018 might send them through the roof.
Already eight US states – Colorado, Washington, Oregon, Alaska, Maine, Massachusetts, Nevada and California – have legalised recreational and medicinal marijuana. However, the HUGE problem is that the federal government in the USA still regards marijuana as illegal, and unbelievably classifies it as the same as heroin and cocaine. This means that none of the US cannabis companies can list on the stock exchange or borrow money from banks — because although legal in their state they are still illegal federally.
Canadian analysts think it could take a few more presidential administrations before marijuana is made “legal” by federal government in the USA, but when it is all bets are off and the sky is the limit for these US companies.
Here are some of the many stocks out there with some information about the companies involved:-
AbbVie is a pharmaceutical company that discovers, develops and markets both biopharmaceuticals and small molecule drugs and is listed on the New York Stock Exchange. Their Marinol drug is FDA-approved for the treatment of nausea in patients undergoing chemotherapy and is also prescribed to AIDS patients suffering from loss of appetite. The drug is made of a synthetic form of THC (one of at least 113 cannabinoids identified in cannabis. THC is the principal psychoactive constituent of cannabis) and is delivered as an oral capsule.
Although the DEA still classifies marijuana as a Schedule I drug, Marinol is listed as a Schedule III drug, meaning the FDA recognizes the clinical benefits and abuse potentials are believed to be lower.
The company sells its products to wholesalers, distributors, government agencies, health care facilities, specialty pharmacies, and independent retailers from its distribution centers and public warehouses.
Aurora Cannabis Inc.
Aurora Cannabis Inc. is based in Vancouver, Canada and focuses on cultivating, harvesting, and selling medical marihuana in Canada. Using water from the Canadian Rocky Mountains, Aurora cannabis plants are brought to harvest in their 55,200 sq. ft. facility. Their state-of-the-art facility is designed to produce the cleanest, safest medical cannabis available on the market and they are focused on providing high quality medical cannabis at affordable pricing.
Canopy Growth Corporation, formerly Tweed Marijuana Inc., is a medical marijuana company based in Smiths Falls, Ontario. It is the largest marijuana cultivator in Canada in terms of production capacity and sales, has the largest share of the Canadian medical marijuana market and is probably going claim a decent chunk of the recreational market as well. The Canadian Parliamentary Budget Officer forecast an annual market size of between $4.2 billion and $6.2 billion for the recreational market, so assuming Canopy’s market share is 20% that equates to an additional $1.2 billion in annual revenue.
Canopy’s partnership with alcoholic-drink maker Constellation Brands was a match made in heaven. This deal made history in the marijuana industry and open the paths for other large companies to ride the marijuana wave as well. Constellation plans to create and market marijuana-infused beer with Canopy, which will drive up the shares of this marijuana stock as well.
Cara Therapeutics Inc.
Cara Therapeutics, Inc. is listed on NASDAQ and is a clinical-stage biopharmaceutical company, focusing on developing and commercializing chemical entities designed to alleviate pain and pruritus (or itching) by selectively targeting kappa opioid receptors. They are developing lead molecules that selectively modulate peripheral cannabinoid (CB) receptors without targeting Central Nervous System cannabinoid receptors. Peripheral CB receptor modulators will be initially developed as a novel therapeutic approach for neuropathic and inflammatory pain, a condition currently without consistently effective therapies. Cara’s most advanced CB compound is currently in preclinical development.
The company is also developing cannabis-based product candidates that target the body’s peripheral nervous system. Its lead product candidate is in Phase III clinical trials for the treatment of acute postoperative pain in adult patients, as well as completed Phase II clinical trials for the treatment of uremic pruritus disease, an intractable systemic itching condition which occurs among people with Chronic Kidney Disease. The company is also developing Oral CR845, which is in Phase IIa clinical trials for the treatment of moderate-to-severe acute and chronic pain.
It has licensing agreements with Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize products in South Korea; and Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products for acute pain and uremic pruritus in Japan.
GT Biopharma Inc.
GT Biopharma is a clinical stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products and a portfolio of central nervous system, or CNS, product candidates. They are continuing their progress with their FDA phase 2 cancer treatment, and beginning phase 1 clinical trials for their Myasthenia Gravis Autoimmune muscular disease.
GW Pharmaceuticals plc
GW Pharmaceuticals plc is a British biopharmaceutical company, listed on NASDAQ, that operates in the United Kingdom, Europe, the United States, Canada, and Asia.
It is a biopharmaceutical company that engages in discovering, developing, and commercializing cannabinoid prescription medicines. They primarily offer Sativex, the first natural cannabis plant derivative to gain market approval in any country, an oromucosal spray for the treatment of spasticity due to multiple sclerosis. It also focuses on the Phase III clinical development program of Sativex for use in the treatment of cancer pain; and Phase 2 trials in other indications, such as neuropathic pain. Their product pipeline includes Epidiolex, a treatment for Dravet syndrome and Lennox-Gastaut syndrome, as well as other product candidates in Phase 1 and 2 clinical development for the treatment of glioma, adult epilepsy, type-2 diabetes, and schizophrenia. In a Phase III trial for Epidiolex, the drug reduced the frequency of seizures by 39% in children with a form of epilepsy known as Dravet syndrome, compared to a 13% reduction in children who took a placebo.
INSYS Therapeutics Inc.
Insys Therapeutics, Inc. is a specialty pharmaceutical company developing and commercializing supportive care products listed on NASDAQ. It has two FDA-approved cannabis-based drugs and seven more drugs in the pipeline. Their Subsys is a spray for breakthrough cancer pain in opioid-tolerant cancer patients in the United States. Its lead product candidate is Syndros, an orally administered liquid formulation of dronabinol (a synthetic form of tetrahydrocannabinol (THC), helps patients with anorexia symptoms related to weight loss from AIDS. The drug was approved by the American regulatory agency as a therapy to stimulate patients’ hunger, as well as a treatment for the nausea and vomiting that is involved with cancer chemotherapy – which is prescribed to patients who do not respond well enough to standard antiemetic (anti-vomiting) treatments. Also in development, Cannabidiol Oral Solution is a synthetic cannabidiol for childhood catastrophic epilepsy syndromes.
MassRoots is one of the largest and most active technology platforms for cannabis consumers, businesses and activists with over 1,000,000 registered users. It is affiliated with some of the leading organizations in the cannabis industry, including the ArcView Group and National Cannabis Industry Association. MassRoots has been making many strides recently with regards to increasing revenue via new advertising functions for the cannabis industry as well as reducing overall expenditures. As the industry expands year over year, platforms like MassRoots will be providing individuals and companies avenues for advertisement as an alternative to Facebook & Google which have shunned cannabis based ads. MassRoots is available in both the Apple App Store and Google Play Store.
MedReleaf is a Licensed Producer of premium cannabis-based products, dedicated to innovation, operational excellence and the production of top-quality cannabis. They trail Canopy Growth as a Canadian Marijuana producer, but are increasing in production capacity in preparation for the adult-use recreational legalization. Since April 2017, MedReleaf has increased its capacity by 80% and since their production costs are low, more revenue will flow right to the bottom line.
Vitality Biopharma, Inc.
Vitality Biopharma is a cure development company, dedicated to unlocking the power of cannabinoid “prodrugs” as a means to treat serious neurological and inflammatory disorders.
A prodrug is a medication or compound that, after administration, is converted in the body into a pharmacologically active drug. They are typically designed to overcome well-known side-effects of currently available therapies. Vitality’s prodrug technology enables the selective targeting of specific tissues or organs, including the gut or brain, enabling the drug to have a more targeted effect.
They have developed a new class of cannabinoid prodrugs, known as cannabosides, which can enable the selective delivery of tetrahydrocannabinol (THC) and cannabidiol (CBD) to the gastrointestinal tract.
Site-specific delivery could enable oral drug formulations of cannabinoids to provide therapeutic benefits while reducing or avoiding the systemic delivery of THC into the bloodstream. Currently, high concentrations of psychoactive THC in the brain limit the dose of cannabinoids that can be used elsewhere in the body for treatment of pain and inflammation.
Independent clinical trial results suggest that cannabinoids will help induce remission in Crohn’s disease patients, and that the vast majority of inflammatory bowel disease (IBD) patients experience symptomatic relief, including 84% of patients who report improvement in visceral or abdominal pain. Approximately 1.4 million Americans have IBD, including Crohn’s disease and ulcerative colitis. Most patients are diagnosed before age 30 and require life-long treatment.
Zynerba Pharmaceuticals Inc.
Zynerba Pharmaceuticals are dedicated to developing next-generation skin-delivered cannabinoid therapeutics for rare and near-rare neuropsychiatric (mental) conditions in patients with high unmet medical needs. They are listed on NASDAQ.
They focus on developing and commercializing proprietary synthetic cannabinoid therapeutics formulated for skin delivery. Its product candidates include ZYN002, which is in Phase I clinical trial for the treatment of refractory epilepsy, Fragile X syndrome, and osteoarthritis; and ZYN001 that is in preclinical stage for the treatment of fibromyalgia and peripheral neuropathic pain.
The state of the marijuana market looks to be more attractive for investors now than ever before. This industry is here to stay and grow and grow! However, I am NOT a financial advisor and am NOT recommending anyone to buy any of these stocks, this is just a list of some of the many stocks out there with some information about the companies involved.
1,293 total views, 1 views today